These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions. Chodock R; Yolkut D; Connolly DR Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814 [TBL] [Abstract][Full Text] [Related]
7. The end of big government? Miller HI Nat Biotechnol; 1997 Feb; 15(2):111. PubMed ID: 9035118 [No Abstract] [Full Text] [Related]
8. Bush tails follow-ons. Fox J Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392007 [No Abstract] [Full Text] [Related]
9. Products in the U.S. pipeline. Pharmaceutical Manufacturers Association. Biotechnology (N Y); 1991 Oct; 9(10):947-9. PubMed ID: 1367805 [No Abstract] [Full Text] [Related]
10. The meaning of the "me-too" drug decision. Archambault GF Hosp Formul; 1975 Oct; 10(10):510. PubMed ID: 10316671 [No Abstract] [Full Text] [Related]
11. Foreign Establishment Registration and United States agent requirements. Nolte CJ; McNamara-Cullinane M Med Device Technol; 2002 Dec; 13(10):32-3. PubMed ID: 12575528 [TBL] [Abstract][Full Text] [Related]
12. Genes out of the bottle. New Repub; 2000 Feb; 222(9):9. PubMed ID: 14582498 [No Abstract] [Full Text] [Related]
13. Biotech patents-business as usual? Lawrence S Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861 [No Abstract] [Full Text] [Related]
14. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results. Falit BP Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220 [No Abstract] [Full Text] [Related]
15. Allied against reform: pharmaceutical industry-academic physician relations in the United States, 1945-1970. Tobbell DA Bull Hist Med; 2008; 82(4):878-912. PubMed ID: 19075387 [TBL] [Abstract][Full Text] [Related]
16. Is the drought over for pharming? Kaiser J Science; 2008 Apr; 320(5875):473-5. PubMed ID: 18436771 [No Abstract] [Full Text] [Related]
17. The disfranchisement of fertile women in clinical trials: the legal ramifications of and solutions for rectifying the knowledge gap. Bowles LE Vanderbilt Law Rev; 1992 May; 45(4):877-920. PubMed ID: 16047448 [No Abstract] [Full Text] [Related]
18. A compilation of government regulation of biotechnology. Hile JP; Keech BH; Gund CK; Connolly WM Bioprocess Technol; 1991; 13():525-44. PubMed ID: 1367150 [No Abstract] [Full Text] [Related]
19. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation. Reed SD; Califf RM; Schulman KA Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727 [TBL] [Abstract][Full Text] [Related]
20. Will we reap what biopharming sows? Miller HI Nat Biotechnol; 2003 May; 21(5):480-1. PubMed ID: 12721561 [No Abstract] [Full Text] [Related] [Next] [New Search]